D.A. Davidson & CO. Acquires 917 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

D.A. Davidson & CO. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 1.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 97,094 shares of the biopharmaceutical company’s stock after purchasing an additional 917 shares during the period. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $7,866,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Tompkins Financial Corp boosted its holdings in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 241 shares during the period. Private Wealth Management Group LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Fortitude Family Office LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $29,000. Sachetta LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $30,000. Finally, Rakuten Securities Inc. bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $33,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD opened at $67.35 on Wednesday. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $83.91 billion, a P/E ratio of 186.92, a price-to-earnings-growth ratio of 1.37 and a beta of 0.22. The firm’s fifty day simple moving average is $68.93 and its two-hundred day simple moving average is $74.75. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.37 earnings per share. As a group, analysts predict that Gilead Sciences, Inc. will post 3.74 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be given a dividend of $0.77 per share. The ex-dividend date is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.57%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on GILD shares. Maxim Group cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Truist Financial downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Royal Bank of Canada lowered their price objective on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research report on Friday, April 26th. Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Finally, StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $83.69.

Read Our Latest Stock Report on Gilead Sciences

Gilead Sciences Company Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.